... Direct In Situ Apoptosis Detection ... situ by the direct TUNEL ... tagged with a directly labeled ... fluorescence staining for 40 samples ...
... BioGenex VISION Sytem is a highly ... with proprietary digital imaging and automation ... image acquisition, analysis, archving/retrieval and colored ... with the industry's fastest scanning and ...
... is used for second-dimension SDS-PAGE sample ... place in PROTEAN Plus cells. Bromophenol ... allow monitoring of electrophoresis runs. The ... in 1x Tris, glycine, SDS, and ...
... a low melting point agarose used for ... strips in place for most applications. Bromophenol ... monitoring of electrophoresis runs. The solution is ... in 1x Tris, glycine, SDS, and 0.003% ...
Biology Products:(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... Dec. 11 Ambit Biosciences Corporation announced today ... M. D. Anderson Cancer Center of the first patient ... E fficacy) Phase 2 pivotal trial ... (AML). AC220 is a novel, orally available, potent ... as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ...
(Date:12/11/2009)... Gwathmey, Inc., a pre-clinical contract research organization and ... cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... experience working with small businesses and the federal ... managed multimillion dollar portfolios for the National Institutes ...
(Date:12/10/2009)... (Nasdaq: DNDN ) announced today that it has ... its common stock at a price to the public ... the underwriters a 30-day option to purchase up to ... overallotments, if any. The offering is expected to ... conditions. ,, J. P. Morgan Securities Inc. and Deutsche ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3Biology NavigationMedical Navigation